Are Irregular & Phantom Periods Normal during Perimenopause?

What Happens to Your Menstrual Cycle during Perimenopause

Perimenopause is the transition window between regular reproductive cycling and menopause, defined retrospectively as 12 consecutive months without a menstrual period. Cycle changes during this window follow a broadly predictable trajectory, even though individual months feel chaotic.

The Stages of Reproductive Aging Workshop +10 (STRAW+10) consensus, published in 2012, provides the most widely adopted clinical framework for classifying this transition 1. Under STRAW+10, early perimenopause (stage -2) begins when cycle length varies by 7 or more days in consecutive cycles. Late perimenopause (stage -1) is marked by amenorrhea of 60 days or longer. These shifts reflect declining ovarian reserve and increasingly erratic follicular recruitment.

Data from the Study of Women's Health Across the Nation (SWAN), a multiethnic longitudinal cohort of over 3,300 women followed from pre-menopause through post-menopause, showed that the median duration of the menopausal transition was approximately 4.5 years, though 10 to 15% of women experienced a transition lasting 8 years or longer 2. The mean age at which persistent cycle irregularity began was 43.5 years, well before the mean age of final menstrual period at 51.4.

This is not a smooth decline. Cycles may shorten to 21 days for several months, then stretch to 45 or 60 days, then briefly return to a 28-day rhythm before disappearing again. That volatility is the hallmark of perimenopause, not a sign that something is wrong.

Why Phantom Periods Happen

Phantom periods are episodes of classic premenstrual or menstrual symptoms (cramping, bloating, breast soreness, headache, irritability, fatigue) that arrive without any bleeding. They confuse women who expect symptoms and bleeding to travel as a pair.

The explanation is hormonal. During a typical ovulatory cycle, the corpus luteum produces progesterone, which stabilizes the endometrium and then withdraws to trigger shedding. During perimenopause, anovulatory cycles become increasingly common. The SWAN study found that by late perimenopause, up to 60% of cycles were anovulatory 3. In an anovulatory cycle, estradiol may still rise and partially stimulate the endometrium, but without a progesterone surge and withdrawal, full shedding does not occur. The estrogen fluctuation itself, however, is enough to trigger the constellation of symptoms women recognize as "period-like."

Dr. Nanette Santoro, Professor of Obstetrics and Gynecology at the University of Colorado School of Medicine and principal investigator of the SWAN endocrine substudy, has described perimenopause as "a time of hormonal chaos, not hormonal decline," noting that estradiol levels often spike unpredictably before they fall 4. These surges explain why some perimenopausal women report symptoms that feel more intense than their reproductive-age cycles, not less.

Prostaglandins, produced by estrogen-primed endometrial tissue, can still cause uterine cramping and gastrointestinal disturbance even when the lining is too thin to shed visibly. Similarly, breast tissue responds directly to estrogen and progesterone receptor activation, producing tenderness regardless of whether a bleed follows.

The Hormonal Mechanics behind Cycle Chaos

Understanding why perimenopause feels so unpredictable requires looking at what ovarian hormones actually do during the transition.

The conventional narrative of "falling estrogen" is misleading for most of the transition. Research published in the Journal of Clinical Endocrinology & Metabolism found that during early perimenopause, mean estradiol levels were actually higher than in premenopausal controls, with more extreme peak-to-trough swings 5. Only in late perimenopause and the year immediately surrounding the final menstrual period did estradiol consistently drop below premenopausal averages.

Progesterone tells a different story. Because anovulatory cycles produce little or no progesterone, the estrogen-to-progesterone ratio shifts dramatically. This "unopposed estrogen" state explains several common perimenopausal complaints: heavier bleeding in cycles that do occur, increased breast tenderness, water retention, and mood symptoms that resemble severe PMS.

Follicle-stimulating hormone (FSH) rises as ovarian inhibin B production declines, but FSH levels during perimenopause are notoriously unreliable for diagnosis. A single FSH measurement can be within the "normal" premenopausal range one week and in the postmenopausal range the next 6. The 2015 NICE guideline on menopause states: "Do not use FSH to diagnose perimenopause in women aged over 45 years with menopausal symptoms, including altered menstrual cycle" 7. Diagnosis is clinical, based on age and symptom pattern, not blood work.

Anti-Mullerian hormone (AMH) correlates more reliably with ovarian reserve depletion, but routine AMH testing is not currently recommended for perimenopausal diagnosis in clinical guidelines. SWAN data showed that AMH levels below 0.20 ng/mL predicted final menstrual period within approximately 5.99 years across all race/ethnicity groups studied 8.

What Bleeding Patterns Are Normal and Which Are Not

Irregular does not mean anything goes. The American College of Obstetricians and Gynecologists (ACOG) distinguishes between expected perimenopausal variability and abnormal uterine bleeding that warrants evaluation 9.

Expected perimenopausal patterns include:

• Cycles ranging from 21 to 60 days
• Occasionally skipping 1 to 3 months, then resuming
• Lighter-than-usual periods alternating with heavier ones
• Spotting between periods (though this should still be mentioned to a clinician)

Patterns that require evaluation regardless of perimenopausal status:

• Soaking through a pad or tampon every hour for 2 or more consecutive hours
• Periods lasting longer than 8 days consistently
• Bleeding between periods that is heavy or persistent
• Any bleeding after 12 months of amenorrhea (postmenopausal bleeding)
• New-onset bleeding after intercourse

The ACOG Practice Bulletin on abnormal uterine bleeding notes that endometrial pathology, including hyperplasia and carcinoma, must be excluded in women over 45 with abnormal bleeding, and in women under 45 with risk factors such as obesity, anovulation, or unopposed estrogen exposure 10.

Transvaginal ultrasound and endometrial biopsy are the primary tools. An endometrial thickness of <4 mm on ultrasound in a postmenopausal woman has a negative predictive value exceeding 99% for endometrial cancer 11. For perimenopausal women with ongoing cycles, endometrial thickness varies with cycle phase, and biopsy becomes the more informative test.

How Long Phantom Periods and Irregularity Last

The duration of cycle chaos varies widely. Short transitions happen. Long ones are more common than most women expect.

SWAN follow-up data showed that the median time from onset of cycle irregularity to final menstrual period was 4.5 years, but the interquartile range was broad: 2.1 to 7.6 years 2. Certain factors predicted longer transitions. Women with higher body mass index (BMI), current smoking, and higher anxiety scores tended to experience longer perimenopausal durations. Black and Hispanic women in the SWAN cohort had somewhat longer transitions than white and Japanese American women, though these differences were partially attenuated after adjusting for BMI and smoking.

Phantom periods often cluster in late perimenopause, when anovulatory cycles are most frequent but the hypothalamic-pituitary-ovarian axis is still generating enough hormonal fluctuation to produce symptoms. They can persist for 1 to 3 years before hormonal output drops low enough that even phantom symptoms stop.

The ACOG Committee Opinion on the menopausal transition notes that women should not assume they have reached menopause until 12 consecutive months of amenorrhea have passed 12. A 3-month or even 6-month gap in bleeding does not confirm menopause. Resumption of bleeding after months of amenorrhea is common and, while usually benign in context, should be discussed with a clinician if it occurs after a prolonged gap.

Managing Symptoms during the Transition

Treatment depends on which symptoms dominate and on individual risk profiles. Several evidence-based options exist.

Hormonal approaches. Low-dose combined oral contraceptives remain a first-line option for perimenopausal women who need both cycle regulation and contraception. A pill containing 20 mcg ethinyl estradiol provides enough estrogen to suppress erratic endogenous production, regularize bleeding, and reduce vasomotor symptoms 13. For women who do not need contraception or who have contraindications to combined hormonal methods, cyclic or continuous progestins (medroxyprogesterone acetate 10 mg for 12 to 14 days per month, or micronized progesterone 200 mg) can induce predictable withdrawal bleeds and protect the endometrium.

Menopausal hormone therapy (MHT, formerly called HRT) becomes the standard approach once a woman reaches menopause. The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) affirms that for symptomatic women under age 60 or within 10 years of menopause onset, the benefits of MHT generally outweigh the risks 14.

Non-hormonal approaches. SSRIs and SNRIs, particularly paroxetine 7.5 mg (the only FDA-approved non-hormonal treatment for vasomotor symptoms at the time of its approval) and venlafaxine 75 mg, reduce hot flashes by 40 to 60% 15. For mood symptoms specifically linked to hormonal flux, these can be started during perimenopause.

Fezolinetant, a neurokinin 3 receptor antagonist, gained FDA approval in May 2023 for moderate-to-severe vasomotor symptoms. The SKYLIGHT 1 trial (N=501) showed that fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by 63.3% at week 12 compared to 46.4% with placebo 16.

Lifestyle interventions with evidence include regular aerobic exercise (associated with modestly reduced vasomotor symptom severity in a Cochrane review, though data quality was low to moderate) and cognitive behavioral therapy for sleep disruption linked to night sweats 17.

When to See a Doctor

Not every irregular cycle requires a clinic visit, but certain triggers should prompt one promptly.

The NAMS 2022 position statement recommends evaluation for any woman experiencing bleeding that meets criteria for acute abnormal uterine bleeding, new postcoital bleeding, or any bleeding after confirmed menopause 14. Beyond bleeding concerns, persistent symptoms that interfere with daily function (severe mood instability, sleep disruption exceeding 3 to 4 nights per week, or vasomotor symptoms affecting work or relationships) also warrant a clinical conversation.

Dr. JoAnn Pinkerton, former executive director of NAMS, has stated: "Women do not need to suffer through perimenopause. We have safe, effective treatments, and the key is matching the right treatment to the right woman at the right time" 14.

Thyroid dysfunction (both hypo- and hyperthyroidism) can mimic or compound perimenopausal symptoms, including cycle irregularity, mood changes, and fatigue. TSH screening is reasonable in any perimenopausal woman whose symptoms are atypical or disproportionate 18. Pregnancy remains possible until menopause is confirmed, and a pregnancy test is always step one when evaluating a missed period in a sexually active perimenopausal woman.

Perimenopause, Bone Health, and Cardiovascular Risk

The perimenopausal transition is also a window of accelerated bone loss and shifting cardiovascular risk that makes symptom management part of a broader health strategy.

SWAN bone-density data demonstrated that the rate of lumbar spine bone mineral density (BMD) loss approximately doubled during the perimenopausal transition compared to premenopausal rates, with the most rapid loss occurring in the 1 to 2 years flanking the final menstrual period 19. Total loss across the transition averaged 5 to 7% at the lumbar spine. This trajectory supports early discussion of bone-protective strategies (weight-bearing exercise, calcium and vitamin D adequacy, and potential pharmacotherapy for high-risk women) well before menopause is reached.

Cardiovascular risk markers also shift during perimenopause. SWAN metabolic data showed that LDL cholesterol increases by approximately 10 to 15% across the menopausal transition independent of aging, driven primarily by estrogen withdrawal effects on hepatic lipid metabolism 20. This makes the perimenopausal visit an appropriate time to establish baseline lipid panels and discuss modifiable risk factors.